Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Zexian Zeng, Ph.D.


This page shows the publications co-authored by Zexian Zeng and Jingxin Fu.
Connection Strength

  1. TISMO: syngeneic mouse tumor database to model tumor immunity and immunotherapy response. Nucleic Acids Res. 2021 Sep 17.
    View in: PubMed
    Score: 0.246
  2. Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network. Clin Cancer Res. 2021 Sep 15; 27(18):5049-5061.
    View in: PubMed
    Score: 0.234
  3. In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target. Cell. 2021 Oct 14; 184(21):5357-5374.e22.
    View in: PubMed
    Score: 0.062
  4. Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade. Cancer Discov. 2021 Jun; 11(6):1524-1541.
    View in: PubMed
    Score: 0.059
  5. Clonal tracing reveals diverse patterns of response to immune checkpoint blockade. Genome Biol. 2020 10 15; 21(1):263.
    View in: PubMed
    Score: 0.058
  6. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020 07 02; 48(W1):W509-W514.
    View in: PubMed
    Score: 0.057
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.